查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球細菌感染治療市場-2022-2029
市場調查報告書
商品編碼
1140665

全球細菌感染治療市場-2022-2029

Global Bacterial Infectious Diseases Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

2021 年細菌感染治療市場價值 758 億美元。預計在預測期內（2022-2029 年）將以 8.2% 的複合年增長率增長。

細菌感染是由引發保護性免疫反應的細菌引起的感染。它涉及體內或體外有害細菌的生長。細菌是在所有環境中發現的單細胞微生物，包括土壤、水和身體。它們以多種形狀存在，包括棒狀（桿菌）、球狀（球菌）和螺旋狀（螺旋藻）。

細菌感染可能發生在身體的許多不同部位，包括喉嚨、肺、皮膚和腸道。細菌感染的特徵在於各種症狀，包括血尿、尿頻、腹瀉、不適、發燒、喉嚨痛、頭痛、咳嗽、疼痛、噁心、嘔吐、皮疹、病變、膿腫和虛弱。細菌感染會增加危及生命的並發症的風險，例如血液中毒、腎功能衰竭和中毒性休克綜合徵。

市場動態

老齡化社會的到來推動市場增長

由於老年人發生細菌感染的風險很高，隨著老年人口的增加，對治療細菌感染的藥物的需求也在增加。由於多種因素，老年人中觀察到嚴重的細菌感染，包括醫療條件、免疫力減弱、不同藥物的共同給藥、診斷延遲以及對治療的反應延遲或降低。

根據聯合國 (UN) 的一份報告，到 2020 年，全球 65 歲及以上的人口將達到 7.27 億。到2050年，老年人口預計將增加一倍以上，達到15億。亞洲的老年人口數量超過歐洲和北美。尿路感染、皮膚感染、胃腸道感染、肺炎和流感在老年人中很常見。

預計抗菌素耐藥性的增加將在預測期內推動治療藥物的開發。

由於耐藥病原體的出現和傳播，抗生素耐藥性正在增加。根據世界衛生組織 (WHO) 新的全球抗菌素監測系統 (GLASS)，在 22 個國家的 50 萬疑似細菌感染者中觀察到抗菌素耐藥性。 2020 年，30 個結核病高負擔國家中約 86% 的新結核病病例。

濫用或過度使用抗生素、無法獲得清潔的水和衛生設施 (WASH)、衛生設施的感染和疾病預防和控制不足、缺乏高質量和負擔得起的藥物、疫苗和診斷工具。有幾個因素正在推動抗菌素阻力，包括缺乏准入、缺乏認識和知識，以及缺乏執法。抗菌素耐藥性限制了最常見的細菌感染的治療。在全球範圍內，由現有抗菌藥物無法治療的多重耐藥菌和泛耐藥菌引起的傳染病正在增加。由於耐藥細菌的這種增加，用於治療細菌感染的治療劑的開髮變得活躍。細菌感染管道很強大，正在開發多種療法。幾家公司正在努力開發有效的治療方法，以克服現有抗生素所表現出的耐藥性。根據世界衛生組織（WHO）的數據，與世界衛生組織優先病原體清單相對應的大約32種抗生素正在臨床開發中。在這 32 種抗生素中，只有 6 種被列為革命性抗生素。

組織和研究機構克服抗菌素耐藥性的努力正在推動市場增長

一些組織和機構正在努力克服抗菌素耐藥性。例如，印度政府在 NCDC 協調的“十二五”規劃中啟動了國家抗菌素耐藥性控制計劃。這種循序漸進的方法包括 35 個州立醫學院實驗室和 26 個州/UT。世界衛生組織 (WHO) 與被忽視疾病藥物倡議 (DNDi) 簽署了全球抗生素研發夥伴關係 (GARDP)。該夥伴關係旨在到 2025 年開發和提供五種新的治療方法，針對被世衛組織確定為最大威脅的耐藥細菌。

美國食品藥品監督管理局 (FDA) 發起了一項“立即生成抗生素激勵措施 (GAIN)”計劃，以通過加快開發和批准新的抗菌劑和抗真菌劑來解決抗菌素耐藥性對公眾健康的威脅。）法律”被頒布。

COVID-19 影響分析

隨著使用抗菌劑治療 COVID-19 患者的細菌感染，隨著 COVID-19 患者人數的增加，細菌感染藥物出現了顯著增長。 COVID-19 感染是由葡萄球菌、腸球菌、肺炎克雷伯菌、腸桿菌、大腸桿菌、不動桿菌和假單胞菌等多種細菌引起的。

根據 Bradley J. Langford 等人 2020 年發表在臨床微生物學和傳染病 (CMI) 上的一項研究，3.5% 的 COVID-19 患者和 14.3% 的 COVID-19 患者發生細菌合併感染. % 被觀察到。大約 71.9% 的 COVID-19 患者接受了抗生素治療細菌感染。主要推薦使用抗生素，如阿奇黴素、頭孢曲松、槲皮素、雷帕黴素和強力黴素。阿奇黴素具有抗炎作用，可用於抑制對 COVID-19 的過度活躍的免疫反應。

流行病學

2019 年全球疾病負擔、傷害和風險因素研究 (GBD) 估計，2019 年類風濕性關節炎 (RA) 的患病率為 326 萬。女性受到影響的可能性是男性的兩到三倍。大約有 12 名女性和 20 名男性中有 1 名在其一生中會患上炎症性自身免疫性風濕病。根據 Giegerich E 等人 2018 年的數據，2017 年克羅恩病的診斷患病率在低收入亞太地區為每 10 萬人 6 人，在高收入亞太地區為每 10 萬人 46 人，在歐洲為每 10 萬人 46 人。在北美，每 10 萬人中有 133 例，每 10 萬人中有 210 例。克羅恩病的確診患病率在 40-54 歲的人群中最高。強直性脊柱炎患病率歐洲為23.8/萬，亞洲為16.7/萬，北美為31.9/萬，拉丁美洲為10.2/萬，非洲為1萬，人均確診7.4。

市場細分

β-內□胺有望在細菌感染治療市場佔據最大份額

按治療劑，市場分為 β-內□胺類、奎諾酮類、大環內酯類、四環素類、磺胺類等。 β-內□胺預計將佔據最大份額，因為它們是用於預防和治療細菌感染的處方最多的抗生素。 β-內□胺通過抑制細胞壁合成起作用。 β-內□胺類抗生素靶向青黴素結合蛋白 (PBP)，該蛋白參與細菌細胞壁的交聯。 β-內□胺類抗生素對廣泛的臨床適應症有效。青黴素類、頭孢菌素類、碳青黴烯類和單環內□胺類是市場上使用最廣泛的β-內□胺類抗生素。

β-內□胺類藥物的研發活動正在加強。例如，2019年3月，Iterum Therapeutics宣布口服和靜脈注射（IV）sulopenem製劑在社區獲得性肺炎、急性細菌性前列腺炎、淋球菌性尿道炎和盆腔炎四個新適應症：獲得合格傳染病產品（ QIDP) 和美國食品和藥物管理局 (FDA) 的快速通道指定。 Sulopenem 還被批准用於治療非複雜性尿路感染 (uUTI)、複雜性尿路感染 (cUTI) 和復雜的腹腔內感染 (cIAI)，符合合格傳染病產品 (QIDP) 和 First I 的跟蹤指定。

通過分銷渠道，預計零售藥店的銷售額在預測期內將快速增長

市場按分銷渠道分為醫院藥房、零售藥房、在線藥房等。由於零售藥店和藥店提供治療細菌感染的藥物，預計零售藥店的市場增長率最高。全球零售商店的數量正在增加。一項橫斷面調查發現，大約 93.5% 的抗生素，包括阿莫西林和復方磺胺甲噁唑，是由大多數註冊藥店開具的。

區域分析

北美在全球治療細菌感染的藥物市場中佔有最大的市場份額。

由於細菌感染的流行率不斷上升，北美地區將在 2021 年佔據全球細菌感染治療市場的最大市場份額。根據美國疾病控制與預防中心 (CDC) 的數據，到 2021 年，結核病將影響美國 7,860 人。 2019 年美國的沙門氏菌和萊姆病也分別佔 58,371 和 34,945 例。抗生素耐藥性感染很普遍。根據美國疾病控制和預防中心 (CDC) 的數據，2019 年每年有超過 280 萬人遭受抗生素耐藥性感染。每年有超過 35,000 人死於抗生素耐藥性感染。

由於大量使用治療劑來治療細菌感染，美國占據了最高的市場份額。根據美國疾病控制和預防中心 (CDC) 的數據，醫療保健專業人員開出的抗生素數量為 2.702 億，即每 1,000 人使用 836 種抗生素。此外，細菌感染治療藥物的批准和上市也在取得進展。例如，2020 年 6 月 4 日，美國食品和藥物管理局批准了 Recarbrio。 Recarbrio 旨在治療 18 歲及以上患者的醫院和呼吸機相關細菌性肺炎。預計在預測期內，抗菌劑的容易獲得將刺激市場增長。

預計亞太地區將在預測期內以最快的複合年增長率增長

由於人口老齡化導致細菌感染的增加，預計亞太地區將成為全球細菌感染治療市場增長最快的地區。 .根據聯合國的一份報告，印度有大約 8700 萬 65 歲以上的人口。此外，增加對醫療設施和基礎設施發展的投資預計將對市場產生積極影響。

用於開發治療細菌感染的治療藥物的研究和開發活動也很活躍。有多個市場參與者正在開發治療細菌感染的療法。人們越來越意識到使用抗菌劑治療細菌感染。預計在預測期內，人口收入和購買力的提高將增加對細菌感染藥物的需求。

競爭格局。

細菌感染治療市場是一個分散的市場，市場參與者眾多。諾華公司、葛蘭素史克公司、輝瑞公司、默克公司、賽諾菲公司、艾爾建公司、拜耳公司、阿斯利康公司、百時美施貴寶公司、武田製藥有限公司、禮來公司、強生公司和梯瓦製藥工業有限公司是具有較大市場份額的主要參與者。公司正在採取多種增長戰略，例如產品批准、產品發布、收購、合併、合作夥伴關係和許可，以增加其市場佔有率。例如：

併購與合作

2019 年 7 月，Nosopharm 與 Evotec SE 合作，將 NOSO-502（一種針對腸桿菌感染的新型抗生素）推進到醫院獲得性和呼吸機相關性肺炎 (HAP/VAP) 的臨床階段開發。已同意開發第二代Odilorhabdin用於治療

產品發布和批准

2019 年 7 月，默克公司獲得了美國食品藥品監督管理局 (FDA) 的批准，用於注射 1.25 克 Recarbrio（亞胺培南、西司他丁、瑞巴坦），這是一種新的聯合抗生素。 Recarbrio 用於治療複雜的尿路感染 (cUTI)，包括由陰溝腸桿菌、大腸桿菌、產氣克雷伯菌、肺炎克雷伯菌和銅綠假單胞菌等易感革蘭氏陰性菌引起的腎盂腎炎，替代治療選擇有限。 18 歲以上的患者有或沒有

2019 年 7 月，默克公司獲得美國食品藥品監督管理局 (FDA) 的批准，用於治療 18 歲及以上患者的醫院獲得性細菌性肺炎和呼吸機相關性細菌性肺炎 (HABP)，用於治療 Zerbaxa（頭孢唑烷和他唑巴坦） ）。/VABP）。

艾爾建批准了 Avycaz（通用名：頭孢他啶、avibactam）的附加適應症，用於治療由以下革蘭氏陰性菌（包括肺炎克雷伯菌）引起的醫院獲得性肺炎和呼吸機相關性細菌性肺炎 (HABP/VABP)：我得到了，所以我得到了會讓你知道的。適用於 18 歲及以上的患者，包括陰溝腸桿菌、大腸桿菌、粘質沙雷氏菌、奇異變形桿菌、銅綠假單胞菌和流感嗜血桿菌。

2019 年 8 月 19 日，美國食品和藥物管理局批准 Zenreta 用於治療成人社區獲得性肺炎。這種新藥為治療社區獲得性細菌性肺炎患者提供了更好的選擇。

接管。

2020 年 2 月，Grifols 收購了抗生素開發商 Aradigum。

2021 年 10 月 11 日，山德士完成了對葛蘭素史克頭孢菌素業務的收購，確認了山德士對抗生素業務的承諾。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按疾病類型劃分的市場細分
  • 按藥物劃分的市場細分
  • 按管理途徑劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 不斷增長的老年人口
      • 細菌感染增加
    • 限制因素
      • 治療藥物的副作用
      • 基因突變
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 法律法規分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按疾病類型

  • 細菌性皮膚感染
  • 食物中毒感染
  • 性傳播疾病
  • 其他

第8章藥物

  • β-內□胺系統
  • 奎諾酮類
  • 大環內酯類
  • 四環素類
  • 磺胺類系統
  • 其他

第 9 章給藥途徑

  • 口語
  • 局部給藥
  • 家長代理
  • 其他

第10章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 13 章公司簡介

  • 諾華公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • GlaxoSmithkline plc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Sanofi
  • Allergan
  • Bayer AG
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Baxter
  • Eli Lilly and Company
  • Johnson and Johnson
  • Insmed, Inc.
  • Otsuka Pharmaceuticals Co., Ltd.
  • Roche Holding AG
  • Forest Laboratories, Inc.
  • Teva Pharmaceuticals Industries Ltd.（LIST NOT EXHAUSTIVE）

第14章 DataM

簡介目錄
Product Code: DMPH2790

Market Overview

Bacterial Infectious Diseases Therapeutics market was valued at USD 75.8 billion in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 8.2% during the forecast period (2022-2029).

Bacterial infectious diseases are infectious diseases occurred due to bacteria that trigger a protective immune response. It involves the proliferation of a harmful strain of bacteria on or inside the body. Bacteria are the single-celled microorganisms found in all sorts of environments, including soil, water bodies, and in or on other bodies. Bacteria are present in different shapes including rod-shaped (bacilli), spherical (cocci), or helical (spirilla).

Bacterial infectious diseases can affect the throat, lungs, skin, bowel and other body parts. Bacterial infectious diseases are characterized by various signs and symptoms including bloody urine, frequent urination, diarrhea, fatigue, fever, sore throat, headache, cough, aches, nausea, vomiting, rashes, lesions, abscesses, weakness, and others. Bacterial infectious diseases increase the risk of causing life-threatening complications, such as blood poisoning, kidney failure, toxic shock syndrome, and others.

Market Dynamics

Growing Older Population is Driving the Growth of the Market

The demand for bacterial infectious diseases therapeutics is increasing with the rising older population as the older population is at a high risk of developing bacterial infectious diseases. Severe bacterial infectious diseases are observed among the older population due to several factors such as medical conditions, weakened immune system, concurrent use of different drugs, delayed diagnosis, delayed or diminished response to therapy.

According to the United Nations (UN) report, the older population of age-group 65 years or above was 727 million worldwide in 2020. The older population is expected to be more than double and reach up to 1.5 billion in 2050. Asia has a higher older population in comparison to Europe and Northern America. Urinary tract infections, skin infections, gastrointestinal infections, pneumonia, influenza, and others are most frequent among the older population.

Increasing Antibacterial Resistance is Expected to Boost the Development of Therapeutics over the Forecast Period.

There is growing antibacterial resistance due to the emergence and spread of drug-resistant pathogens. According to the World Health Organization (WHO)'s new Global Antimicrobial Surveillance System (GLASS), antibiotic resistance was observed among 500,000 people with suspected bacterial infections across 22 countries. Approximately, 86% of new TB cases in 30 high TB burden countries in 2020.

Several factors such as misuse and overuse of antibacterial, lack of access to clean water, sanitation and hygiene (WASH), poor infection and disease prevention and control in healthcare facilities, poor access to quality, affordable medicines, vaccines and diagnostics, lack of awareness and knowledge, and lack of enforcement of legislation are causing the antibacterial resistance. The antibacterial resistance is limiting the treatment of the most frequent bacterial infectious diseases. There is a rising spread of multi- and pan-resistant bacteria infections not being treatable by using the existing antibacterial worldwide. The increasing antibacterial resistance has resulted in the rising development of therapeutics for the treatment of bacterial infectious diseases. The pipeline of bacterial infectious diseases is robust with the involvement of several therapeutics being developed. Several companies are developing therapeutics that is effective in overcoming the resistance demonstrated by existing antibacterial. According to the World Health Organization (WHO), there are approximately 32 antibiotics in clinical development that address the WHO list of priority pathogens. Out of these 32 antibiotics in the pipeline, only six were classified as innovative.

Rising Organizations & Institutes Initiatives for Overcoming the Antibacterial Resistance is Fueling the Market Growth

Several organizations & institutes have raised initiatives for overcoming antibacterial resistance. For instance, The India government has launched a "National Programme on AMR Containment during the 12th five-year plan, which is coordinated by NCDC. This phased manner included 35 state medical college labs and 26 states/UT. World Health Organization (WHO) had entered into the Global Antibiotic Research and Development Partnership (GARDP) with the Drugs for Neglected Diseases Initiative (DNDi). This partnership aims at developing and delivering the five new treatments that target drug-resistant bacteria identified by WHO as posing the greatest threat by 2025.

The United States Food and Drug Administration (FDA) has passed the Generating Antibiotic Incentives Now (GAIN) act for addressing the public health threat of antibacterial drug resistance by stimulating the development and approval of new antibacterial and antifungal drugs.

COVID-19 Impact Analysis

The bacterial infectious diseases therapeutics has witnessed drastic growth with the increasing number of people suffering from the COVID-19 as the antibacterial are being used for the treatment of bacterial infections among the patients with COVID-19. Various bacteria species such as Staphylococcus spp., Enterococcus spp., Klebsiella pneumonia, Enterobacter spp., Escherichia coli, Acinetobacter spp., and Pseudomonas spp are causing the infection among the patients with COVID-19.

According to the Bradley J. Langford et.al., 2020 study published in clinical microbiology & infection (CMI), bacterial co-infection was observed among 3.5% of COVID-19 patients and 14.3% of COVID-19 patients. Approximately, 71.9% of COVID-19 patients received antibiotics for the treatment of bacterial infections. Antibiotics such as azithromycin, ceftriaxone, quercetin, rapamycin, doxycycline, and other antibiotics are mostly recommended among the patients. Azithromycin has demonstrated the anti-inflammatory effects that can be useful for reducing an overactive immune response to COVID-19.

Epidemiology

According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, the estimation that the prevalence of Rheumatoid Arthritis (RA) was resulted in 3.26 million in 2019. Women are two to three times as likely to be affected in comparison to men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn's Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn's Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.

Market Segment Analysis

Beta-Lactam segment is expected to hold the largest share in the Bacterial Infectious Diseases Therapeutics market

By therapeutics, the market is classified as beta-lactam, quinolones, macrolides, tetracyclines, sulfonamide, and others. The Beta-lactam segment is anticipated to hold the largest share as it is the most prescribed antibacterial for the prevention & treatment of bacterial infection. The beta-lactam acts by inhibiting cell wall synthesis. It targets the penicillin-binding proteins (PBPs) involved in the cross-linking of the bacterial cell wall. B-Lactam antibiotics are effective against a broad range of clinical indications. Penicillin's, cephalosporins, carbapenems, and monobactams are the beta-lactam antibacterial with the highest market penetration.

There is increasing research and development activities for beta-lactam therapeutics. For instance, in March 2019, Iterum Therapeutics had received Qualified Infectious Disease Product (QIDP) and Fast Track Designations from the United States Food and Drug Administration (FDA) for its oral and intravenous (IV) formulations of sulopenem in four new indications including the community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory disease. Sulopenem had also received the Qualified Infectious Disease Product (QIDP) and Fast Track Designations for the treatment of uncomplicated urinary tract infection (uUTI), complicated urinary tract infection (cUTI), and complicated intra-abdominal infection (cIAI).

By Distribution Channel, Retail Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The retail pharmacies are segmented to have the highest market growth due to the high availability of therapeutics for the treatment of bacterial infectious diseases in the retail pharmacies & drug stores. There is an increase in the number of retail stores across the globe. According to the cross-sectional survey, approximately 93.5% of antibiotics including amoxicillin and trimethoprim-sulfamethoxazole were prescribed by the majority of the registered drug shops.

Geographical Analysis

North America region holds the largest market share global Bacterial Infectious Diseases Therapeutics market

North America region is dominating the global bacterial infectious diseases therapeutics market accounted for the largest market share in 2021 owing to the increasing prevalence of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the incidence cases of tuberculosis was 7,860 in the United States in 2021. The total number of incidence cases of salmonella and Lyme disease was 58,371 and 34,945 respectively in the United States in 2019. There is a growing prevalence of antibacterial resistant infections. According to the Centers for Disease Control and Prevention (CDC), every year more than 2.8 million people were affected by antibiotic-resistant infections 2019. Every year more than 35,000 people died due to antibiotic-resistant infections.

The United States accounts for the highest market share due to the higher usage of therapeutics for the treatment of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the healthcare providers had prescribed 270.2 million antibiotic prescriptions i.e., 836 antibiotic prescriptions per 1000 persons. There is rising approval & launch of therapeutics for the treatment of bacterial infectious diseases. For instance, on 4th June 2020, the United States Food and Drug Administration approved Recarbrio. The Recarbrio is to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients 18 years of age and older. The easy availabilities of the antibacterial shall stimulate the market growth over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global bacterial infectious disease therapeutics market owing to the increasing prevalence of bacterial infectious diseases with the increasing older population. According to the United Nations Report, there were around 87millions of the population of age-group 65 years or over in India. The increasing investment for the improvement of the healthcare facilities & infrastructure shall have a positive impact on the market.

There is increasing research and development activities for the development of therapeutics for the treatment of bacterial infectious diseases. There is a presence of several market players developing therapeutics for the treatment of bacterial infectious diseases. There is growing awareness regarding the use of antibacterial for the treatment of bacterial infection. The increasing domestic income and purchasing power of people shall boost the demand for bacterial infectious diseases therapeutics over the forecasted period.

Competitive Landscape:

The bacterial infectious diseases therapeutics market studied is a fragmented market with the presence of a large number of market players. Novartis AG, GlaxoSmithkline Plc, Pfizer Inc, Merck & Co., Inc., Sanofi, Allergan, Bayer AG, AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson and Johnson, and Teva Pharmaceuticals Industries Ltd. are the major market players with the significant market share. Companies are adopting several growth strategies such as product approvals, product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers & Collaborations:

In July 2019, Nosopharm had entered into the collaboration with Evotec SE for advancing the NOSO-502, a novel antibiotic class against Enterobacteriace infections to the clinical stage of development and develop a second-generation Odilorhabdin for the treatment of hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP)

Product Launch & Approvals:

In July 2019, Merck & Co. had received approval from the United States Food and Drug Administration (FDA) for the Recarbrio (imipenem, cilastatin, and relebactam) injection, 1.25 grams, a new combination antibacterial. Recarbrio is recommended for the patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms such as Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumonia, and Pseudomonas aeruginosa.

In July 2019, Merck & Co. had received the approval for Zerbaxa (ceftolozane and tazobactam) from the United States Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.

Allergan plc had received the approval to expand the use of Avycaz (ceftazidime and avibactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms including the Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenza in patients 18 years of age or older.

On 19th August 2019, The United States Food and Drug Administration approved Xenleta to treat adults with community-acquired bacterial pneumonia. This new drug provides a better option for treating patients with community-acquired bacterial pneumonia.

Acquisition:

In February 2020, Grifols had acquired the Aradigm, an antibiotic developer.

On 11th October 2021, Sandoz completed the acquisition of GSK's cephalosporin business, confirming Sandoz's commitment to the antibiotics business.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Therapeutics
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Older Population
      • 4.1.1.2. Increasing Prevalence of Bacterial Infectious Diseases
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse Effects of Therapeutics
      • 4.1.2.2. Genetic Mutations
      • 4.1.2.3. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 7.3. Market Attractiveness Index, By Disease Type Segment
    • 7.3.1. Bacterial Skin Infections*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Foodborne Bacterial Infections
    • 7.3.3. Sexually Transmitted Bacterial Infections
    • 7.3.4. Others

8. By Therapeutics

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  • 8.3. Market Attractiveness Index, By Therapeutics Segment
    • 8.3.1. Beta-Lactam*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Quinolones
    • 8.3.3. Macrolides
    • 8.3.4. Tetracyclines
    • 8.3.5. Sulfonamide
    • 8.3.6. Others

9. By Route of Administration

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3. Market Attractiveness Index, By Route of Administration Segment
    • 9.3.1. Oral*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Topical
    • 9.3.3. Parenteral
    • 9.3.4. Others

10. By Distribution Channel

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3. Market Attractiveness Index, By Distribution Channel Segment
    • 10.3.1. Hospitals Pharmacies*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
    • 10.3.4. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Novartis AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. GlaxoSmithkline plc
  • 13.3. Pfizer Inc.
  • 13.4. Merck & Co., Inc.
  • 13.5. Sanofi
  • 13.6. Allergan
  • 13.7. Bayer AG
  • 13.8. AstraZeneca Plc
  • 13.9. Bristol-Myers Squibb Company
  • 13.10. Takeda Pharmaceutical Company Limited
  • 13.11. Baxter
  • 13.12. Eli Lilly and Company
  • 13.13. Johnson and Johnson
  • 13.14. Insmed, Inc.
  • 13.15. Otsuka Pharmaceuticals Co., Ltd.
  • 13.16. Roche Holding AG
  • 13.17. Forest Laboratories, Inc.
  • 13.18. Teva Pharmaceuticals Industries Ltd. (LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us